<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04469686</url>
  </required_header>
  <id_info>
    <org_study_id>CHS1221</org_study_id>
    <secondary_id>2019-003596-19</secondary_id>
    <nct_id>NCT04469686</nct_id>
  </id_info>
  <brief_title>Phase 3 Study to Evaluate the Safety and Efficacy of Hydrocortisone Acetate Suppositories</brief_title>
  <official_title>3-Arm Randomized Placebo Controlled Double Blind Phase 3 Study to Evaluate Safety and Efficacy of Once-Daily and Twice-Daily Hydrocortisone Acetate 90 mg Suppository Administered With a Sephure Applicator in Subjects With Ulcerative Colitis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Cristcot LLC</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Cristcot HCA LLC</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Cristcot LLC</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>Yes</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      A randomized, multi-center, double-blind, three arm placebo-controlled study in male and
      non-pregnant, non-lactating female subjects aged 18 years to examine the safety and efficacy
      of two dosing regimens of hydrocortisone acetate 90 mg suppository administered with the
      Sephure applicator for the treatment of ulcerative colitis of the rectum.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Hydrocortisone acetate 90 mg or placebo will be administered as a rectal suppository with a
      Sephure suppository applicator. Two arms of the study will receive different dosage regimens
      of hydrocortisone acetate, and the third arm will receive placebo. All subjects will
      administer the study drug twice a day; once in the morning and once in the evening for 28
      days.

      The study population will consist of male and non pregnant, non lactating females aged 18
      years and older with a confirmed diagnosis of active UC of the rectum.
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">July 10, 2020</start_date>
  <completion_date type="Anticipated">December 31, 2021</completion_date>
  <primary_completion_date type="Anticipated">December 31, 2021</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Clinical remission measured using the Modified Mayo Score</measure>
    <time_frame>28 days</time_frame>
    <description>To evaluate the the efficacy of two dosage regimens of the study drug</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Reduction of stool frequency measured using Mayo Scoring sub score of stool frequency</measure>
    <time_frame>28 days</time_frame>
    <description>To assess the change in stool frequency</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Rectal bleeding measured using Mayo Scoring sub-score of rectal bleeding equal to 0</measure>
    <time_frame>28 days</time_frame>
    <description>To assess the change in rectal bleeding</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Quality of Life assessed measured using IBDQ validated questionnaire</measure>
    <time_frame>28 days</time_frame>
    <description>To examine the quality of life of patients</description>
  </other_outcome>
  <other_outcome>
    <measure>Grading of disease severity measure using Mayo Scoring sub-score of Physician's Global Assessment</measure>
    <time_frame>28 days</time_frame>
    <description>To assess disease severity</description>
  </other_outcome>
  <other_outcome>
    <measure>Concentrations of hydrocortisone acetate using pharmacokinetic sampling</measure>
    <time_frame>28 days</time_frame>
    <description>To evaluate the exposure of hydrocortisone acetate levels for safety</description>
  </other_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">618</enrollment>
  <condition>Ulcerative Proctitis</condition>
  <arm_group>
    <arm_group_label>Twice Daily - Active</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Twice daily 90 mg hydrocortisone acetate suppository administered with Sephure suppository applicator</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Once Daily - Active</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Once daily 90 mg hydrocortisone acetate and once daily placebo suppository administered with Sephure suppository applicator</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Twice daily placebo suppository administered with Sephure suppository applicator</description>
  </arm_group>
  <intervention>
    <intervention_type>Combination Product</intervention_type>
    <intervention_name>Twice daily 90 mg hydrocortisone acetate suppository administered with Sephure applicator</intervention_name>
    <description>Twice daily 90 mg hydrocortisone acetate suppository administered with Sephure applicator</description>
    <arm_group_label>Twice Daily - Active</arm_group_label>
    <other_name>Twice Daily - Active</other_name>
  </intervention>
  <intervention>
    <intervention_type>Combination Product</intervention_type>
    <intervention_name>Once daily 90 mg hydrocortisone acetate or placebo suppository administered with Sephure applicator</intervention_name>
    <description>Once daily 90 mg hydrocortisone acetate or placebo suppository administered with Sephure applicator</description>
    <arm_group_label>Once Daily - Active</arm_group_label>
    <other_name>Once Daily - Active</other_name>
  </intervention>
  <intervention>
    <intervention_type>Combination Product</intervention_type>
    <intervention_name>Twice daily placebo suppository administered with Sephure applicator</intervention_name>
    <description>Twice daily placebo suppository administered with Sephure applicator</description>
    <arm_group_label>Placebo</arm_group_label>
    <other_name>Twice Daily - Placebo</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Male or non pregnant, non lactating females aged 18 years and older.

          -  Subjects with a confirmed diagnosis of active UC of the rectum, extending no more than
             15 centimeters (cm) (5.9 inches) proximal to the anal verge as assessed by colonoscopy
             performed at Visit 2. Note: Subjects may have a history of more extensive UC (e.g.,
             pancolitis), but have active disease only in the rectum at the time of enrollment.

          -  Modified Mayo sub score for stool frequency of 1 3.

          -  Modified Mayo sub score for rectal bleeding of 0 2.

          -  Modified Mayo endoscopic sub score of 2 3.

          -  Total Modified Mayo Score (without physician global assessment) of 3-8.

        Exclusion Criteria:

          -  History or current diagnosis of bacterial or other infectious colitis, radiation
             enteritis and radiation proctitis, Crohn's disease, collagenous colitis and
             indeterminate colitis.

          -  Prior gastrointestinal surgery except appendectomy, cholecystectomy, and hernia.

          -  Concomitant active lower gastrointestinal disease (except Irritable Bowel Syndrome) or
             distortion of intestinal anatomy.

          -  Bleeding hemorrhoids at the time of enrollment.

          -  Acute diverticulitis at the time of enrollment.

          -  Acute or chronic pancreatitis at the time of enrollment.

          -  Unmanaged celiac disease at the time of enrollment.

          -  Positive stool test for enteric pathogens, Clostridium difficile, or presence of ova
             and parasites.

          -  Taking a prohibited medication.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Mark C Ensign</last_name>
    <phone>978-212-6380</phone>
    <email>mark.ensign@cristcot.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Lead Scientist</last_name>
    <phone>978-212-6380</phone>
    <email>research@cessa-uc.com</email>
  </overall_contact_backup>
  <link>
    <url>http://cessa-uc.com</url>
    <description>A clinical study to evaluate the safety and effectiveness of an investigational hydrocortisone acetate 90 mg suppository administered with the Sephure applicator for the treatment of moderate to severe ulcerative colitis</description>
  </link>
  <verification_date>July 2020</verification_date>
  <study_first_submitted>July 2, 2020</study_first_submitted>
  <study_first_submitted_qc>July 9, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">July 14, 2020</study_first_posted>
  <last_update_submitted>July 9, 2020</last_update_submitted>
  <last_update_submitted_qc>July 9, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">July 14, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Proctitis</mesh_term>
    <mesh_term>Ulcer</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hydrocortisone</mesh_term>
    <mesh_term>Hydrocortisone 17-butyrate 21-propionate</mesh_term>
    <mesh_term>Hydrocortisone acetate</mesh_term>
    <mesh_term>Hydrocortisone hemisuccinate</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

